Add Metformin as the Next Step
For a patient with A1c 7.9% on Jardiance 25 mg who cannot take GLP-1 receptor agonists, add metformin immediately if not already prescribed, or if already on metformin, add a DPP-4 inhibitor (linagliptin preferred given the existing SGLT2 inhibitor). 1
Rationale and Treatment Algorithm
First: Confirm Metformin Status
The 2025 ADA Standards explicitly recommend metformin as foundational therapy for type 2 diabetes unless contraindicated 1. Since your patient is on Jardiance alone:
If NOT on metformin: Add metformin immediately, titrating to 2000 mg daily (or maximum tolerated dose). This combination (SGLT2i + metformin) is FDA-approved and demonstrated A1c reductions of 0.6-0.8% in clinical trials 2.
If ALREADY on metformin: Proceed to add a third agent (see below).
Second: If Already on Metformin + Jardiance
With A1c still at 7.9% (0.9% above the typical 7.0% target), you need triple therapy. Since GLP-1 agonists are contraindicated, your best options are:
Primary Recommendation: Add DPP-4 Inhibitor (Linagliptin 5 mg)
- The combination of empagliflozin + linagliptin + metformin achieved A1c reductions of 1.08-1.24% from baseline in treatment-naive patients 3
- As add-on to metformin, empagliflozin 25 mg + linagliptin 5 mg reduced A1c by 1.19% versus 0.62% with empagliflozin alone 4
- 61.8% of patients achieved A1c <7% at 24 weeks with this triple combination 4
- Excellent safety profile with no hypoglycemia requiring assistance 4, 3
- Complementary mechanisms: SGLT2i (renal glucose excretion) + DPP-4i (incretin enhancement) + metformin (hepatic glucose production)
Alternative: Add Basal Insulin
- Consider if A1c remains >1.5% above goal or if symptoms of hyperglycemia exist 1
- Start with 10 units daily or 0.1-0.2 units/kg
- Titrate by 2 units every 3 days targeting fasting glucose 80-130 mg/dL
- Caution: Higher hypoglycemia risk; requires glucose monitoring and patient education
Third-Line Alternative: Add Pioglitazone
- Empagliflozin 25 mg added to pioglitazone (with or without metformin) reduced A1c by 0.69% versus placebo over 76 weeks 5
- Major caveats: Weight gain, fluid retention, heart failure risk, bone fracture risk in women, bladder cancer concerns
- Generally avoided unless specific insulin resistance features present
Key Clinical Considerations
Why Not Sulfonylureas?
While technically an option, sulfonylureas carry significant hypoglycemia risk, promote weight gain, and lack cardiovascular/renal benefits that characterize modern diabetes therapy. The 2025 guidelines de-emphasize their use 1.
Cardiovascular and Renal Context
The 2021 ESC/ADA guidelines prioritize SGLT2 inhibitors (which your patient already has) for cardiovascular and renal protection 6. Since she's already on maximum-dose Jardiance:
- Ensure she has appropriate cardiovascular risk assessment
- Monitor for albuminuria and eGFR
- The SGLT2i provides MACE reduction, heart failure hospitalization reduction, and CKD progression prevention independent of glucose lowering 6
Monitoring Plan
After adding therapy:
- Recheck A1c in 3 months
- If A1c remains >7.5% despite triple therapy, consider basal insulin addition
- Monitor for genital mycotic infections (SGLT2i effect) and gastrointestinal symptoms (metformin/DPP-4i)
- No increased hypoglycemia risk with this combination 4, 3
Cost and Access Considerations
If cost is prohibitive for DPP-4 inhibitors, metformin intensification (if not at maximum dose) or addition of sulfonylurea becomes pragmatic, though less ideal. Basal insulin (NPH) remains the most cost-effective injectable option if needed 1.
The evidence strongly supports DPP-4 inhibitor addition to your current SGLT2i + metformin regimen, with linagliptin specifically studied in combination with empagliflozin showing superior efficacy and excellent tolerability. 4, 3